Product Description
potent inhibitor of bacterial type IIA topoisomerases
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Respiratory Tract Infections|Cross Infection|Gram-Negative Bacterial Infections|Soft Tissue Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01039610 |
NCT01039610 | P1 |
Withdrawn |
Respiratory Tract Infections|Gram-Negative Bacterial Infections|Cross Infection|Soft Tissue Infections |
2010-08-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00517673 |
BTI107248 | P1 |
Completed |
Respiratory Tract Infections|Soft Tissue Infections |
2008-09-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|